FDA & Government News

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

Share

5 Key Takeaways

  • 1

    FDA approved Penmenvy vaccine for ages 10-2

  • 2

    Targets major serogroups of Neisseria meningitidis.

  • 3

    Supported by phase III trial data.

  • 4

    Aims to improve vaccination coverage, especially for IMD caused by serogroup B.

  • 5

    U.S. CDC to vote on recommendations in February 202

Original Source(s)

FDA Approves GSK’s 5-in-1 MenABCWY Vaccine

FDA approves GSK’s Penmenvy, a 5-in-1 meningococcal vaccine for adolescents and young adults, targeting five major serogroups of Neisseria meningitidis that cause invasive meningococcal disease.

  • by Kathryn Wighton

  • February 17, 2025

  • 2 min

Related Content

Are Antibiotics Needed for Pediatric Pneumonia?

Study: U.S. Child Allergy Rates Shifted During Pandemic

How Does Trisomy 21 Affect Fetal Hematopoiesis?

Fetal hematopoietic stem cells in Down syndrome are 'primed' for differentiation, as revealed by single-cell multi-omics of over 1.1 million cells, potentially explaining early hematological abnormalities.